Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Famciclovir
Drug ID BADD_D00868
Description Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Indications and Usage For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
Marketing Status approved; investigational
ATC Code J05AB09; S01AD07
DrugBank ID DB00426
KEGG ID D00317
MeSH ID D000077595
PubChem ID 3324
TTD Drug ID D0VT8P
NDC Product Code 65862-466; 42291-416; 64980-351; 0093-8117; 31722-707; 60505-3246; 63187-919; 63187-920; 64980-350; 51927-5177; 53104-7616; 33342-024; 55289-168; 71205-609; 64980-349; 69875-8015; 42291-415; 63629-7890; 0093-8118; 31722-706; 31722-708; 60505-3247; 65862-467; 0093-8119; 33342-025; 71052-199; 63187-998; 51552-1626; 65862-465; 65977-0047; 60505-3245; 65862-486; 33342-026; 42291-414
UNII QIC03ANI02
Synonyms Famciclovir | 9-(4-Acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine | 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester) | BRL 42810 | BRL-42810 | BRL42810 | Famvir
Chemical Information
Molecular Formula C14H19N5O4
CAS Registry Number 104227-87-4
SMILES CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myalgia15.05.02.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuralgia17.02.07.005--
Neutropenia01.02.03.004--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Paranoia19.05.01.005--Not Available
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.016--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.045--
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Musculoskeletal disorder15.03.05.025--Not Available
Lipase13.05.01.011--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages